BR112023021215A2 - Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos - Google Patents

Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos

Info

Publication number
BR112023021215A2
BR112023021215A2 BR112023021215A BR112023021215A BR112023021215A2 BR 112023021215 A2 BR112023021215 A2 BR 112023021215A2 BR 112023021215 A BR112023021215 A BR 112023021215A BR 112023021215 A BR112023021215 A BR 112023021215A BR 112023021215 A2 BR112023021215 A2 BR 112023021215A2
Authority
BR
Brazil
Prior art keywords
compounds
alkynylphenylbenzamide
pharmaceutical composition
compound
protein kinase
Prior art date
Application number
BR112023021215A
Other languages
English (en)
Inventor
Feng Jin
Jie Wang
Ke Ding
Shuang Xiang
Shuihua Zhang
Xia Tang
Xiaoyun Lu
Xun He
Zhang Zhang
Zhengchao Tu
Zhenwei Li
Zhimin Zhang
Zuqin Wang
Original Assignee
Shenzhen Newdel Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Newdel Biotech Co Ltd filed Critical Shenzhen Newdel Biotech Co Ltd
Publication of BR112023021215A2 publication Critical patent/BR112023021215A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos. a presente invenção está relacionada a um composto alquinilfenilbenzamida e ao uso do mesmo. o composto alquinilfenilbenzamida da presente invenção tem uma estrutura conforme apresentada na fórmula (i), pode ser usado como um inibidor de proteína quinase, pode inibir efetivamente a atividade de uma proteína quinase trk e pode inibir a proliferação, migração e invasão de várias células tumorais, e também possui características de boa farmacocinética e baixa toxicidade. (i)
BR112023021215A 2021-04-13 2021-09-09 Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos BR112023021215A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110395086 2021-04-13
PCT/CN2021/117495 WO2022217821A1 (zh) 2021-04-13 2021-09-09 炔苯基苯酰胺类化合物及其应用

Publications (1)

Publication Number Publication Date
BR112023021215A2 true BR112023021215A2 (pt) 2023-12-19

Family

ID=78958920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021215A BR112023021215A2 (pt) 2021-04-13 2021-09-09 Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos

Country Status (8)

Country Link
US (1) US11834454B2 (pt)
EP (1) EP4324833A1 (pt)
JP (1) JP2024514015A (pt)
KR (1) KR20230170938A (pt)
CN (1) CN113831344B (pt)
AU (1) AU2021440841A1 (pt)
BR (1) BR112023021215A2 (pt)
WO (1) WO2022217821A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027792A1 (en) * 2022-08-05 2024-02-08 Shenzhen Newdel Biotech Co., Ltd. Protein kinase degrading agent, medicament and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101436303B1 (ko) * 2005-12-23 2014-09-02 어리어드 파마슈티칼스, 인코포레이티드 비시클릭 헤테로아릴 화합물
CN103596568A (zh) * 2011-04-07 2014-02-19 阿里亚德医药股份有限公司 治疗帕金森病的方法以及组合物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
WO2015085972A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
WO2018089736A1 (en) * 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use

Also Published As

Publication number Publication date
KR20230170938A (ko) 2023-12-19
US11834454B2 (en) 2023-12-05
AU2021440841A1 (en) 2023-10-19
CN113831344A (zh) 2021-12-24
JP2024514015A (ja) 2024-03-27
WO2022217821A1 (zh) 2022-10-20
CN113831344B (zh) 2022-09-16
EP4324833A1 (en) 2024-02-21
US20230046126A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
BR112023021215A2 (pt) Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
BR112012033253A2 (pt) novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
Li et al. Sulforaphane prevents rat cardiomyocytes from hypoxia/reoxygenation injury in vitro via activating SIRT1 and subsequently inhibiting ER stress
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
Finkel Intracellular redox regulation by the family of small GTPases
BR112021017620A2 (pt) Compostos macrocíclicos
BR112022003564A2 (pt) Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método
BR112022021476A2 (pt) Inibidores de quinases heteroaril halogenado e outros heterocíclicos e usos dos mesmos
DOP2022000121A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
BR112022022669A2 (pt) Inibidores de nek7 quinase
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
BR112023002112A2 (pt) Composto para direcionar e degradar proteínas, e método para preparar o mesmo e uso do mesmo
KR102322443B1 (ko) 코직산을 안정적으로 함유하는 피부 미백용 화장료 조성물
BR112023000588A2 (pt) Derivados de piridazina como inibidores de alk5 e/ou alk4
BR112021017829A2 (pt) Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer
BR112021019491A2 (pt) Composto contendo quinolila e composição farmacêutica, e uso dos mesmos
EA202092291A1 (ru) Соединение на основе хинолина или хиназолина и его применение
KR20150062272A (ko) 코직산을 안정적으로 함유하는 피부 미백용 화장료 조성물
BR112023016986A2 (pt) Compostos de aminopirimidina e métodos de seu uso
BR112023005174A2 (pt) Composição anticoccidiana compreendendo folhas de ginkgo e uso da mesma